tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Leukemia D007938 74 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Hematoma D006406 5 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Crohn Disease D003424 12 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Cholestasis D002779 23 associated lipids
Fibrosis D005355 23 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Thyroid Diseases D013959 8 associated lipids
Sinusitis D012852 9 associated lipids
Leukocytosis D007964 9 associated lipids
Glomerulonephritis D005921 35 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Hypoglycemia D007003 13 associated lipids
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Pancytopenia D010198 6 associated lipids
Nervous System Diseases D009422 37 associated lipids
Ataxia D001259 20 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Brain Edema D001929 20 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Gingivitis D005891 3 associated lipids
Periodontal Pocket D010514 9 associated lipids
Brain Infarction D020520 17 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Stroke D020521 32 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Brain Ischemia D002545 89 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Ischemia D007511 18 associated lipids
Glycosuria D006029 10 associated lipids
Seizures D012640 87 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nerve Degeneration D009410 53 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Hypertension D006973 115 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Dermatitis D003872 30 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Vomiting D014839 21 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Pharyngitis D010612 2 associated lipids
Shock D012769 11 associated lipids
Erythema D004890 22 associated lipids
Dermatomycoses D003881 17 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Cholelithiasis D002769 16 associated lipids
Fever D005334 35 associated lipids
Amenorrhea D000568 4 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Thrombocytopenia D013921 15 associated lipids
Hyperlipidemias D006949 73 associated lipids
Shock, Septic D012772 11 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Cough D003371 19 associated lipids
Paraproteinemias D010265 2 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Translocation, Genetic D014178 20 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Ovarian Cysts D010048 4 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Cardiomegaly D006332 31 associated lipids
Hypertension, Renal D006977 9 associated lipids
Metaplasia D008679 7 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Tachycardia D013610 7 associated lipids
Cicatrix D002921 9 associated lipids
Neutropenia D009503 15 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Urticaria D014581 13 associated lipids
Behcet Syndrome D001528 7 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Thrombophlebitis D013924 6 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
HIV Seropositivity D006679 15 associated lipids
Uveitis D014605 14 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Doi R et al. Biochemical characterization of the effects of FK506 on signal transduction in exocytotic function of rat pancreatic acini. 1993 J. Pharmacol. Exp. Ther. pmid:7679738
Propper DJ et al. Effects of the immunosuppressive macrolides rapamycin and FK 506 in high responder rats presensitized to major histocompatibility complex antigens. 1993 Transplant. Proc. pmid:7679837
Stock PG et al. Standard sequential immunosuppression with Minnesota antilymphoblast globulin and cyclosporine vs FK 506: a comparison of early nephrotoxicity. 1993 Transplant. Proc. pmid:7679838
Tabasco-Minguillan J et al. Long-term insulin requirement after liver transplantation with FK 506 in American veterans. 1993 Transplant. Proc. pmid:7679839
Klintmalm GB et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679840
Gunji Y et al. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. 1993 Transplant. Proc. pmid:7679841
Gregory CR et al. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 1993 Transplant. Proc. pmid:7679842
Zeevi A et al. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. 1993 Transplant. Proc. pmid:7679843
Inoue T et al. Isolation of mitochondrial cyclophilin from bovine heart. 1993 Biochem. Biophys. Res. Commun. pmid:7679902
Krentz AJ et al. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. 1993 Diabetes pmid:7694879
Jayaraman T and Marks AR Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. 1993 J. Biol. Chem. pmid:7503980
D'Ambrosio R et al. Validation and quality assurance program for monitoring tacrolimus (FK 506) concentrations in plasma and whole blood. 1993 Ther Drug Monit pmid:7504339
Dutz JP et al. A role for calcineurin in degranulation of murine cytotoxic T lymphocytes. 1993 J. Immunol. pmid:7681074
Reese JC et al. The effect of FK506 on canine bile flow. 1993 Transplantation pmid:7504342
Takeguchi N et al. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. 1993 Transplantation pmid:7681229
Woodle ES et al. FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. 1993 Transplantation pmid:7504346
Valdivia LA et al. Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. 1993 Transplantation pmid:7681230
Jindal RM et al. Effect of deoxyspergualin on the endocrine function of the rat pancreas. 1993 Transplantation pmid:7504347
Fujimura A et al. Chronopharmacokinetic study of a new immunosuppressive agent, FK 506, in mice. 1993 Jpn. J. Pharmacol. pmid:7681489
Kodama M et al. FK506 therapy of experimental autoimmune myocarditis after onset of the disease. 1993 Am. Heart J. pmid:7504393
Nishinaka Y et al. Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart. 1993 J. Cardiovasc. Pharmacol. pmid:7681507
Luan S et al. Immunosuppressants implicate protein phosphatase regulation of K+ channels in guard cells. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7681590
Doi R et al. Structural and functional changes of exocrine pancreas induced by FK506 in rats. 1993 Gastroenterology pmid:7681795
Rotonda J et al. Improved calcineurin inhibition by yeast FKBP12-drug complexes. Crystallographic and functional analysis. 1993 J. Biol. Chem. pmid:7681823
Yoshizawa K et al. Establishment of Epstein-Barr virus-associated lymphoma cell line SUBL with t(2;3)(p11;q27) from a liver transplant patient. 1993 Cancer Genet. Cytogenet. pmid:7506636
Peters DH et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. 1993 Drugs pmid:7506654
Mühl H et al. Cyclosporin derivatives inhibit interleukin 1 beta induction of nitric oxide synthase in renal mesangial cells. 1993 Eur. J. Pharmacol. pmid:7506668
Nagata K et al. Failure of FK-506, a new immunosuppressant, to prevent cerebral vasospasm in a canine two-hemorrhage model. 1993 J. Neurosurg. pmid:7692019
Simek SL et al. Sequence and localization of a novel FK506-binding protein to mouse chromosome 11. 1993 Genomics pmid:7507077
Lhoëst G et al. Isolation and identification by FAB mass spectrometry and NMR spectroscopy of a demethylated metabolite of FK506 from erythromycin-induced rabbit liver microsomes. 1993 Pharm Acta Helv pmid:7692454
Izumi S and Okuhara M [FK506 and kifunensine, new immunomodulators of microbial origin]. 1993 Tanpakushitsu Kakusan Koso pmid:7692469
Wakugami T et al. Effect of FK506 on the development of diabetes in BB rats in comparison with that of cyclosporin. 1993 Tohoku J. Exp. Med. pmid:7692621
Quesniaux VF Immunosuppressants: tools to investigate the physiological role of cytokines. 1993 Bioessays pmid:7507316
Hill CC et al. Penile prosthesis surgery in the immunosuppressed patient. 1993 Transplantation pmid:7692633
Roberts JP et al. Reversal of chronic rejection after treatment failure with FK506 and RS61443. 1993 Transplantation pmid:7692634
Storb R et al. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. 1993 Transplantation pmid:7692635
McDiarmid SV et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. 1993 Transplantation pmid:7692636
Yatscoff RW et al. Comparison of the effect of rapamycin and FK506 on release of prostacyclin and endothelin in vitro. 1993 Clin. Biochem. pmid:7507804
Sato M et al. FK506 inhibits phytohemagglutinin-, but not interferon-gamma-, induced HLA-DR antigen expression and accessory cell function on primary cultured human thyroid cells. 1993 Acta Endocrinol. pmid:7509103
White DJ Immunosuppression for heart transplantation. 1993 Br. J. Biomed. Sci. pmid:7694717
Clipstone NA and Crabtree GR Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. 1993 Ann. N. Y. Acad. Sci. pmid:7509131
Takahara S Efficacy of FK506 in renal transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7509132
Thomson AW et al. Incidence of CD4+ IL-2R alpha+ and CD4+ CD45RA+ T-cells in progressive multiple sclerosis and the influence of short-term (3 months) FK 506 therapy. 1993 Ann. N. Y. Acad. Sci. pmid:7509133
Blaehr H et al. Acute effects of FK506 and cyclosporine A on cultured human proximal tubular cells. 1993 Eur. J. Pharmacol. pmid:7683267
Textor SC et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. 1993 Transplantation pmid:7685934
Kadmon M et al. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. 1993 Gastroenterology pmid:7683296
Denesyuk AI et al. Structural similarity of the binding sites of cyclophilin A-cyclosporin A and FKBP-FK506 systems. 1993 Biochem. Biophys. Res. Commun. pmid:7683466
Waschulewski IH et al. Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro. 1993 Br. J. Pharmacol. pmid:7683567
Ohtake M et al. Enhanced liver regeneration in rats treated with 15-deoxyspergualin alone and in combination with FK 506. 1993 Gastroenterol. Jpn. pmid:7683616
Ohnishi H et al. Natural killer cell may impair liver regeneration in fulminant hepatic failure. 1993 Gastroenterol. Jpn. pmid:7683619
McDiarmid SV et al. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. 1993 Transplantation pmid:7685933
Moutabarrik A et al. Use of FK 506 in kidney transplantation. 1993 Transplant. Proc. pmid:7685946
Moutabarrik A et al. Effect of FK 506 and cyclosporine on the expression of IL-6 and its receptor on stimulated monocytes. 1993 Transplant. Proc. pmid:7685949
Takaya S et al. Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. 1993 Transplant. Proc. pmid:7685953
Murphy MP and Morris RE Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. 1993 Transplant. Proc. pmid:7685955
Li W and Handschumacher RE Specific interaction of the cyclophilin-cyclosporin complex with the B subunit of calcineurin. 1993 J. Biol. Chem. pmid:7686148
Wong PY et al. Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. 1993 J. Hepatol. pmid:7686192
Sakr MF et al. FK 506 pre-treatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion. 1993 J. Hepatol. pmid:7686193
Fenton M and Kay JE Thapsigargin activates lymphocytes via a different pathway from ionomycin. 1993 Biochem. Soc. Trans. pmid:7510649
Henke W and Jung K Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin A on rat kidney mitochondria. 1993 Biochem. Pharmacol. pmid:7690566
Murase N et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. 1993 Transplantation pmid:7682735
Schmid FX Prolyl isomerase: enzymatic catalysis of slow protein-folding reactions. 1993 Annu Rev Biophys Biomol Struct pmid:7688608
Lyson T et al. Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. 1993 Circ. Res. pmid:7688670
Morkawa K et al. Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro. 1993 Clin. Exp. Immunol. pmid:7688676
Yamaoka K et al. Cyclosporin A and FK506 block the negative signaling mediated by surface IgM cross-linking in normal human mature B cells. 1993 Immunol. Lett. pmid:7688712
Smith DF et al. Two FKBP-related proteins are associated with progesterone receptor complexes. 1993 J. Biol. Chem. pmid:7688746
Jacobs JC et al. Pyoderma gangrenosum in infancy. 1993 J. Am. Acad. Dermatol. pmid:7688775
Garrity GM et al. Genetic relationships among actinomycetes that produce the immunosuppressant macrolides FK506, FK520/FK523 and rapamycin. 1993 J. Ind. Microbiol. pmid:7688970
Hoof T et al. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin. 1993 Eur. J. Pharmacol. pmid:7689059
Jin YJ and Burakoff SJ The 25-kDa FK506-binding protein is localized in the nucleus and associates with casein kinase II and nucleolin. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7689229
Starzl TE et al. Allograft and xenograft acceptance under FK-506 and other immunosuppressant treatment. 1993 Ann. N. Y. Acad. Sci. pmid:7689809
Reem GH et al. FK-506 inhibits the IL-2-independent induction of the activation antigen CD 69. 1993 Ann. N. Y. Acad. Sci. pmid:7689811
Mollison KW et al. Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7689812
Tai PK et al. P59 (FK506 binding protein 59) interaction with heat shock proteins is highly conserved and may involve proteins other than steroid receptors. 1993 Biochemistry pmid:7689858
Lieberman R FK506, artificial intelligence and pharmacoeconomics. 1993 J Clin Pharmacol pmid:7690045
McMichael J et al. An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. 1993 J Clin Pharmacol pmid:7690046
Jain AB et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. 1993 J Clin Pharmacol pmid:7690047
Cheng JW et al. 15N NMR relaxation studies of the FK506 binding protein: backbone dynamics of the uncomplexed receptor. 1993 Biochemistry pmid:7690248
Zuany-Amorim C et al. Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice. 1993 Br. J. Pharmacol. pmid:7694762
Fingar DC et al. Dissociation of pp70 ribosomal protein S6 kinase from insulin-stimulated glucose transport in 3T3-L1 adipocytes. 1993 J. Biol. Chem. pmid:7679106
Griffiths EJ and Halestrap AP Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. 1993 J. Mol. Cell. Cardiol. pmid:7512654
McCaffrey PG et al. NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. 1993 J. Biol. Chem. pmid:7679116
Armitage JM et al. Pediatric lung transplantation. The years 1985 to 1992 and the clinical trial of FK 506. 1993 J. Thorac. Cardiovasc. Surg. pmid:7679172
Ito K and Komatsu Y [Drug induced hemolytic uremic syndrome]. 1993 Nippon Rinsho pmid:7679450
Hirasé Y et al. Transplantation of long-term cryopreserved allocutaneous tissue by skin graft or microsurgical anastomosis: experimental studies in the rat. 1993 Plast. Reconstr. Surg. pmid:7679796
Langrehr JM et al. Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. 1993 Transplantation pmid:7679526
Uemoto S et al. Experience with FK506 in living-related liver transplantation. 1993 Transplantation pmid:7679528
Talento A et al. A single administration of LFA-1 antibody confers prolonged allograft survival. 1993 Transplantation pmid:7679531
Sattler M et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. 1992 Sep-Oct Drug Metab. Dispos. pmid:1385058
Bowman H and Lennard TW Immunosuppressive drugs. 1992 Nov 4-17 Br J Hosp Med pmid:1282440
Nazer H et al. FK 506 associated disorders in liver transplantation. 1992 May-Jun J. Gastroenterol. Hepatol. pmid:1377038
Arai S et al. The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. 1992 Jul-Aug J. Heart Lung Transplant. pmid:1379829
Fagiuoli S et al. FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. 1992 Jul-Aug Ital J Gastroenterol pmid:1381245
Tong J et al. Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. 1992 Jul-Aug Haematologica pmid:1385279
Mizuno K et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. 1992 Jan-Feb Anticancer Res. pmid:1373592
Japanese study of FK 506 on kidney transplantation: 2. Follow-up study of FK 506-treated patients. 1992 Transpl. Int. pmid:14621874
Chen TS et al. Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. 1992 J. Antibiot. pmid:1372307
Sigal NH and Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. 1992 Annu. Rev. Immunol. pmid:1375473
Minoda M et al. Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice. 1992 Microbiol. Immunol. pmid:1282197
Arceci RJ et al. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. 1992 Blood pmid:1381629